Our VISION
We seek to ensure that endoscopic biopsies can always achieve a definitive diagnosis to enable optimal and timely cancer treatment.
In order to improve the endoscopic experience for both the endoscopist and the patient, we aim to provide:
- Faster, more efficient biopsy yields
- Highly consistent results, regardless of physician skill level
- Easily replicable method to achieve a definitive diagnosis for histological and genetic testing
Introducing Precision™
Designed to always achieve a definitive diagnosis for histologic and genetic testing of endoscopic biopsy tissues.
Precision™, the intellectual property of Limaca Medical, has not been cleared for use at this time by the FDA and is not available in the United States.
IMPROVING THE STANDARD OF CARE
Manual EUS needles represent the traditional standard of current endoscopic biopsy devices. The limitations of these manual tools force physicians to experience:
- Non-diagnostic biopsy rates
- High skill dependency
- Low standardization
- Repeated passes, and many throws
- Less optimal tissue at times for histology, or biologic structure
- Higher rates of inadequate biopsy tissue during molecular analysis testing
PRECISION
DESIGNED TO MEET OR EXCEED ALL CUSTOMER NEEDS- Automated, no user-dependency
- 1 Pass, 2-3 controlled cores obtained
- Far shorter procedure
- Precise control
- Excellent tissue quality
vs.
STANDARD OF CARE
CURRENT ENDOSCOPICBIOPSY DEVICES
- Manual tool, user-dependent
- 2-5 Passes, 30-50 stabs
- Time consuming
- Imprecise
- Fragmented, inconsistent sample quality
First-in-human clinical study
pRELIMINARY OUTCOMES OF AN ONGOING STUDY, ASSESSING INITIAL 9 COMPARATIVE CASES
Data was released in a scientific poster presentation at the American College of Gastroenterology’s 2021 Annual Scientific Meeting.
| Initial 9 Cases | EUS Fine Needle Biopsy (Manual) | Precision™ EUS Biopsy (Automated) |
|---|---|---|
Sampling Time (Minutes) | 5.64 | 3.87 (p=0.001) |
Total Procedure Average Throws/Activations | 55 | 5 (p=0.00002) |
Histology Scores Average
(Scale of 1-5, 5 being the best) | 3.2 | 4.6 (p=0.002) |
CORE SAMPLES
precision™ vs. standard of care
Core biopsy samples were taken in a pre-clinical study on June 26th, 2022, comparing Precision’s automated mechanism to a fine needle biopsy representing today’s highest standard of care.
PRECISION™
Contiguous 110mm core biopsy sample
STANDARD OF CARE
Fragmented, no segment greater than 10mm
HISTOLOGY
AUTOMATED precision™ vs. MANUAL FNB
AUTOMATED PRECISION™
Intact, voluminous, preserved tissue samples
Adequate for cyto- and histopathologic diagnoses, and molecular tumor profiling
MANUAL FNB
Fragmented tissue, detached epithelial strips, with admixed blood
Adequate for categorical cytologic diagnosis, sometimes agnosis
ADDRESSING THE NEED
We are dedicated to applying our technology to make a significant improvement in the delivery of endoscopic biopsy diagnosis in pancreatic, liver, and lung cancers.
The following data represents the deaths and new annual incidence cases related to these deadly cancers that occur in the United States alone. Cancer incidence is the number of new cancer cases arising in a specified population over a given period of time.¹
FDA BREAKTHROUGH
precision™ determined to qualify for designation as a breakthrough device
Precision™ is considered to offer the potential to enhance patient outcomes through more effective treatment or improved diagnosis of life-threatening conditions. This designation will expedite the development and evaluation of our novel device.
HEAR FROM KEY OPINION LEADERS
Our field is driving toward patient centric individualized cancer therapy, known as Precision Medicine, which requires consistently high quality and quantity of endoscopic biopsy tissue, enabling optimal matching of the tumor's genetic profile to personalize a patient's treatment plan.”
RECENT developments AT LIMACA MEDICAL
LIMACA MEDICAL ACCEPTED AS A FINALIST IN THE 2023 AGA SHARK TANK
Five companies, including Limaca Medical, were selected for the 2023 AGA Shark Tank to show a glimpse of the future of GI patient care. The AGA Shark Tank took place on March 10th during the annual AGA Tech Summit.
LIMACA MEDICAL COMPLETES 24 FIRST-IN-HUMAN CASES
Precision™ continues to be tested to gauge its effectiveness in a clinical setting.
MEET LIMACA'S LEADERSHIP
CARL RICKENBAUGH
CEO
Former VP of Business Development & Management Board at Bard Peripheral Vascular & Biopsy for 13 years
Former VP Bus Dev & Strategy at EQT PE Company: Clinical Innovations
Abbott Laboratories: sales, marketing & product development leadership for 13 years
Current Chairman Omeq Medical
Current board member Paragonix Technologies
MBA Georgetown University, Washington DC
ASSAF KLEIN
GENERAL MANAGER & INVENTOR
20 years of experience in medical device companies
Managerial/R&D positions in the fields of gastroenterology, spine, & cardiovascular
Former CEO, MediValve
Projects include implantable devices and delivery systems
MBA Bar-Ilan University; B.Sc., Mechanical Engineering, Technion Institute of Technology, Israel
OUR PARTNERS
The Company was established in Trendlines Labs, and in partnership with Rambam Health Care with the support of the Israel Innovation Authority.
In April of 2022, Limaca Medical partnered with HekaBio, an exclusive Japan commercialization partner that provides operational capability for market entry.
Find the latest news
Limaca Medical and HekaBio Announce Japan Partnership
YOKNEAM, Israel, May 16, 2022 -- Limaca Medical and HekaBio K.K. announced today that they have inked a strategic partnership agreement, whereby HekaBio is to distribute Limaca's Precision-GI™ Endoscopic Biopsy Device in Japan...
Limaca Medical Receives FDA Breakthrough Device Designation
YOKNEAM, Israel, May 2, 2022 -- Limaca Medical announced today that its Precision-GI™ Endoscopic Ultrasound Biopsy Product has received a Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA").
Limaca Medical Raises $1.25 Million to Enhance Precision Medicine Through Improved Biopsies
MISGAV, Israel, Nov. 10, 2020 -- Limaca Medical, a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), a leading Israel- and Singapore-based investment group focused on high-growth medical and agrifood technologies, announced it has closed $1.25 million of a $1.5 million round to complete first-in-human ("FIH") procedures, post-market clinical studies, and obtain regulatory approvals...
References and Disclaimers
- GLOBOCAN 2020 https://gco.iarc.fr/
Precision™ has not been cleared for use at this time by the FDA and is not available in the United States.
This website has been prepared by Limaca Medical Ltd. (the “Company”) solely for informational purposes.
The information contained herein has been prepared to assist prospective investors in making their own evaluation of the Company and does not purport to be complete or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the company and the data set forth in this information. The Company has prepared this site based on information available to it, including information derived from public sources that have not been independently verified. The Company makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any errors or omissions.
This website includes certain statements and estimates provided by the company with respect to the projected future performance of the Company. Such statements, estimates and projections reflect various assumptions by management concerning possible anticipated results, which assumptions may or may not be correct. No representations are made as to the accuracy of such statements, estimates or projections. This site may contain statements that are not historical facts, referred to as “forward looking statements.” The Company’s actual future results may differ materially from those suggested by such statements. No assurance can be given that future events will occur or that projections will be achieved. Past performance is not a reliable indication of future performance. This site is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of the Company’s securities, or an offer to sell, or a solicitation of an offer to buy, the Company’s securities in any jurisdiction. Neither this site nor anything in it shall form the basis of any contract or commitment. Prospective investors should not construe the contents of this site as business, legal, tax, investment or other advice. Each prospective investor should make his, her or its own inquiries and consult his, her or its own advisors as to the appropriateness and desirability of an investment in the Company and as to business, legal, tax and related matters concerning an investment in the company.
An investment in the Company shall be allowed only to such number and category of investors in accordance with applicable laws and regulations and pursuant to a predetermined process. Accordingly, detailed information in connection with the investment shall be revealed and delivered only to a limited number of qualifying investors as provided by law.
3 Ha’Rimon Street
Mevo-Carmel Science and Industry Park 1925000
Ein Ha’Emeq Israel.
info@limaca-medical.com